Based on these data and on the fact that the expression of a functional Rb protein is considered as a prerequisite for responsiveness to CDK4/6 inhibitors, at least a subset of HCC patients may benefit from treatment with these drugs. The gene discussed is CDK4; the disease is hepatocellular carcinoma.